Journals / Respiratory Case Reports / 2018 / Cilt: 7 - Sayı: 2

Steroid Tedavisi Alan HIV Seronegatif Sistemik Lupus Eritematozisli bir Hastada Atipik Görünümlü Pnömosistis Pnömonisi

Pneumocystis Pneumonia with Atypical Presentation in an HIV Seronegative Patient with Systemic Lupus Erythematosus during Steroid Therapy

Pages
82–85
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Trimetoprim / Sülfametaksazol tedavisi 14 gün uygulandı ve klinik iyileşme gözlendi.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pnömosistis pnömonisi (PP) HIV'li hastalarda sık görü- lürken sistemik lupus eritematozisli (SLE) gibi otoimmün hastalığı olanlarda nadirdir.
📊
Key Findings & Data:Yüksek doz steriod kullanımı, ağır hastalık, böbrek tutulumu, lenfosit ve CD4+sayısında düşüklük gibi bazı nedenler SLE hastalarında PP için risk oluşturabilmektedir.
💡
Conclusion & Impact:Trimetoprim / Sülfametaksazol tedavisi 14 gün uygulandı ve klinik iyileşme gözlendi.
🔬Design:Experimental Field Trial
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Pnömosistis pnömonisi (PP) HIV'li hastalarda sık görü- lürken sistemik lupus eritematozisli (SLE) gibi otoimmün hastalığı olanlarda nadirdir. Yüksek doz steriod kullanımı, ağır hastalık, böbrek tutulumu, lenfosit ve CD4+sayısında düşüklük gibi bazı nedenler SLE hastalarında PP için risk oluşturabilmektedir. Burada, yüksek doz steroid tedavi alan SLE'li 23 yaşındaki kadın olgu sunulmuştur. Steroid dozu azaltıldığı sırada kuru öksürük ve devam eden ateş yakınmaları ile kliniğe yatırıldı. Yüksek çözünürlüklü toraks tomografisinde, intraseptal kalınlaşmalar, subplevral nodüller ve 4L, 6 ve 7 nolu lenf nodlarında büyüme saptandı. İndükte balgam örneğinin PCR ile yapılan incelemesinde Pneumocystis jirovecii pozitif bulundu. Trimetoprim / Sülfametaksazol tedavisi 14 gün uygulandı ve klinik iyileşme gözlendi.

Özet

Pneumocystis pneumonia (PCP) is common among HIV patients, but it is rare in patients with autoimmune diseases such as systemic lupus erythematosus (SLE). Some of the risk factors related to PCP in SLE patients include a high steroid dose, greater disease activity, renal involvement, and lower lymphocyte and CD4+ counts. Described herein is the case of a 23- year-old female with SLE who was treated with highdose steroid therapy. She was admitted to the clinic with a dry cough and a prolonged fever persisting since the tapering of the steroid dose. High-resolution computed tomography of the thorax revealed intraseptal thickening, subpleural nodules, and enlargement of the 4L, 6, and 7 lymph nodes. A laboratory examination of an induced sputum sample using polymerase chain reaction was positive for Pneumocystis jirovecii. Trimethoprim / sulfamethoxazole was administered for 14 days and clinical improvement was observed.

🔖

Cite This Article

AMANDA, G., SUTOYO, D. K. (2018). Steroid Tedavisi Alan HIV Seronegatif Sistemik Lupus Eritematozisli bir Hastada Atipik Görünümlü Pnömosistis Pnömonisi. Respiratory Case Reports, Cilt: 7 - Sayı: 2, 82–85. https://ajindex.com/articles/302421

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004
  2. [CrossRef] 2. Calderon EJ, Gutierrez-Rivero S, Durand-Joly I, Dei-Cas E. Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther 2010
  3. [CrossRef] 3. Chen M, Tian X, Qin F, Zhou J, Liu J, Wang M, et al. Pneumocystis pneumonia in patients with autoimmune diseases: a retrospective study focused on clinical characteristics and prognostic factors related to death. PLoS One 2015
  4. e0139144. [CrossRef] 4. Tsai MJ, Chou CW, Lin FC, Chang SC. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy. Lupus 2012
  5. [CrossRef] 5. Weng CT, Liu MF, Weng MY, Lee NY, Wang MC, Lin WC, et al. Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan. J Clin Rheumatol 2013
  6. [CrossRef] 6. Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 2011
  7. [CrossRef] 7. Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 2009
  8. [CrossRef] 8. Mori S, Sugimoto M. Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations. Clin Med Insights Circ Respir Pulm Med 2015
  9. 9(Suppl 1):29-40. [CrossRef] 9. Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 2012
  10. [CrossRef] 10. Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol 2012
  11. W555-61. [CrossRef] 11. Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014
  12. [CrossRef] 12. Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 2008
  13. [CrossRef] 13. Aceves-Avila FJ, Benites-Godinez V. Drug allergies may be more frequent in systemic lupus erythematosus than in rheumatoid arthritis. J Clin Rheumatol 2008
  14. [CrossRef] 14. Anevlavi